July 30th 2025
Three-year follow-up data from the TRAILBLAZER-ALZ 2 extension trial supported early initiation and limited-duration dosing.
Adding Icosapent Ethyl to Statin Therapy Cuts Stroke Risk, Analysis of REDUCE-IT Trial Finds
March 17th 2021International Stroke Conference 2021: A new analysis of the landmark REDUCE-IT trial found that adding icosapent ethyl to treatment regimens that already include statins further reduces stroke risk.